SteadyMed Therapeutics is a technology company.
SteadyMed Therapeutics has raised $12.0M across 2 funding rounds.
SteadyMed Therapeutics has raised $12.0M in total across 2 funding rounds.
SteadyMed Therapeutics has raised $12.0M in total across 2 funding rounds.
SteadyMed Therapeutics's investors include KB Partners, Camber Creek.
SteadyMed Therapeutics is a specialty pharmaceutical company that develops innovative drug delivery systems, primarily through its proprietary PatchPump® platform. This wearable, prefilled, and preprogrammed disposable injector is designed to deliver large-volume and viscous injectable drugs, including biologics, in a controlled, precise, and patient-friendly manner. SteadyMed serves patients requiring parenteral therapeutics, aiming to improve their quality of life by providing a compact, easy-to-use alternative to traditional infusion methods. The company has demonstrated growth momentum through its unique technology and eventual acquisition by United Therapeutics in 2018[1][3][4].
SteadyMed was founded to address the challenges faced by patients dependent on large doses of intravenous and subcutaneous medications. The idea emerged from the need to extend the limits of parenteral therapeutics by creating a device that is simple, smart, and scalable. The PatchPump® leverages proprietary ECell technology, enabling it to deliver viscous drugs accurately under high pressure while maintaining a slim, discreet profile. Early traction included developing a platform that is fully owned and IP protected by SteadyMed, which attracted partnerships and ultimately led to its acquisition by United Therapeutics[1][4].
SteadyMed rides the growing trend of wearable drug delivery systems and personalized medicine, addressing the increasing demand for patient-centric therapies that improve adherence and quality of life. The timing is favorable due to advances in biologics and injectable therapies requiring precise, convenient delivery methods outside clinical settings. Market forces such as rising chronic disease prevalence and healthcare cost containment further drive adoption of such technologies. By innovating in parenteral drug delivery, SteadyMed influences the ecosystem by enabling pharmaceutical companies to develop new formulations that can be administered more easily and safely at home[1][3][4].
Following its acquisition by United Therapeutics, SteadyMed’s PatchPump® platform is positioned to expand its impact through integration with broader therapeutic portfolios and increased commercialization efforts. Future trends shaping its journey include the rise of digital health integration, remote patient monitoring, and the growing shift towards self-administration of complex therapies. SteadyMed’s influence is likely to evolve as it helps redefine standards for injectable drug delivery, potentially enabling new treatment paradigms and improving patient autonomy in chronic disease management[4].
SteadyMed Therapeutics has raised $12.0M across 2 funding rounds. Most recently, it raised $10.0M Venture Round in September 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2012 | $10.0M Venture Round | KB Partners | |
| Jan 1, 2009 | $2.0M Series A | Camber Creek |